Siemens Healthineers sun sami izinin amfani da gaggawa na FDA don gwajin rigakafin SARS-CoV-2

New York-Makon da ya gabata, Hukumar Abinci da Magunguna ta ba Siemens Healthineers izinin amfani da gaggawa don gwajin Advia Centaur SARS-CoV-2 IgG ko sCOVG.
Chemiluminescence immunoassay an ƙirƙira shi don gano ƙimar ƙimar immunoglobulin G ko IgG akan SARS-CoV-2 a cikin jini da jini.Ana gudanar da gwajin akan Siemens' Advia Centaur XP, Advia Centaur XPT da Advia Centaur CP tsarin rigakafi.
A cewar FDA, ana iya amfani da wannan gwajin ta kowane dakin gwaje-gwaje da aka amince da CLIA don yin gwaje-gwaje masu matsakaici ko hadaddun.
A cikin Maris na wannan shekara, SARS-CoV-2 IgG immunoassay wanda Siemens AG ke gudanarwa, wanda ke da hedkwata a Erlangen, Jamus, akan mai nazarin Atellica IM, ya sami EUA daga FDA.
Takardar kebantawa.Sharuɗɗa da sharuɗɗa.Haƙƙin mallaka © 2021 GenomeWeb, sashin kasuwanci na Crain Communications.duk haƙƙin mallaka.